Buruli ulcer

Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer)

Purpose of this document

While the medical community awaits the results of further drug treatment trials, patients may benefit from the knowledge gained to date. This provisional guidance is intended to help health workers in endemic areas to provide better management of M. ulcerans disease.

Share
Email Twitter Facebook Google Delicious LinkedIn
More...

Table of contents

  1. Background
  2. Growing evidence on the role of specific antibiotics
  3. Purpose of this document
  4. Important notes for health workers
  5. Case definitions3
  6. When to suspect M. ulcerans disease
  7. Antibiotics administration and dosages
  8. Treatment
  9. Documenting M. ulcerans disease and monitoring response during and after treatment
  10. Patient information and compliance
  11. Follow-up after antibiotic treatment
  12. Reporting of experiences
  13. Implementation of this guidance
  14. Monitoring
  15. Important issues to consider
  16. Provision of antibiotics
  17. References
  18. Annex 1 - Information on rifampicin, streptomycin and amikacin4
  19. Annex 2 - Treatment cards for inpatient and outpatient use
  20. Annex 3 - Patient register
  21. Annex 4 - Follow-up form after antibiotic treatment
  22. Acknowledgements